Ilepatril

DB06604InvestigationalSmall molecule

Investigated for use/treatment in hypertension.

Mechanism: Pharmacologically active on Angiotensin-converting enzyme and Neprilysin
Curator reviewed
Primary indication: Investigated for use/treatment in hypertension.Curator reviewed
Formula / weight: C₂₂H₂₈N₂O₅S · 432.533 g/mol (avg)
Code names: AVE-7688

Resolves to

Compound

Structure

InChIKeyFXKFFTMLFPWYFH-RDGPPVDQSA-NSMILES[H][C@]12CCC[C@H](N1C(=O)[C@H](CC1=C2C=CC=C1)NC(=O)[C@@H](SC(C)=O)C(C)C)C(O)=O

Targets

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

10+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ilepatril, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.